Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda’s Adzynma Approved in Europe, Launch Set for September
August 9, 2024
- Japan Ethical Drug Sales Down 5.5% in June: Crecon
August 9, 2024
- Daiichi, Merck Expand ADC Deal into Harpoon’s T-Cell Engager
August 8, 2024
- Chugai Gets Japan Rights to Roche’s Anti-TL1A IBD Drug
August 8, 2024
- Anapeine Restriction Forcing Sandoz to Curb Supply of More Local Anesthetics
August 7, 2024
- Sandoz to Discontinue Paxil AGs as Originator Pulls Out
August 7, 2024
- Kyorin, Jikei Startup Ink Option Deal for Respiratory Disease Treatment
August 7, 2024
- NCC Offshoot’s 1st CAR-T Therapy Set to Enter Clinic Next Year: CEO
August 7, 2024
- Santen Axes Diquas LX Outlook to Zero for Now as Supply Halt Continues
August 7, 2024
- Santen Snags Asian Rights to Cloudbreak’s Topical Pterygium Drug
August 7, 2024
- Keytruda Tops Japan Sales Ranking for 10th Straight Month: Encise
August 7, 2024
- Japan CDMO Market Up Only Slightly in 2023 as COVID Windfall Falters: Report
August 7, 2024
- LEO Pharma Wins Approval for Pen Version of Adtralza
August 6, 2024
- Shionogi’s Antibiotic Cefiderocol Accepted for Review in China
August 6, 2024
- Japan Major Pharmas Endure Market Crash, but Biotechs Take a Hit
August 6, 2024
- Kyowa Kirin’s H1 Sales up 16.9% on North American Biz, Strategic Brands
August 5, 2024
- Kyowa Kirin Not Ruling Out Small Molecule Drug Research: CMO
August 5, 2024
- Otsuka Wants to Make Jnana Cornerstone of Future Drug Discovery: CEO
August 5, 2024
- Takeda Announces Reorganization, Buyout Program in Japan
August 5, 2024
- Daiichi Sankyo Kicks Off Global PIII Study for B7-H3-Directed ADC
August 5, 2024
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…